Regulus Therapeutics | RGLS - Selling And Administration Expenses

Regulus Therapeutics reported $4.44M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Selling And Administration Expenses Change
Alnylam Pharmaceuticals ALNY:US USD 210.34M 25.52M
AstraZeneca AZN:LN USD 3.53B 174M
Astrazeneca AZN:US USD 3.53B 174M
Biogen BIIB:US USD 632.8M 69.5M
Celldex Therapeutics CLDX:US USD 6.6M 68K
Gilead Sciences GILD:US USD 2.02B 807M
GlaxoSmithKline GSK:LN GBP 2.44B 467M
Intercept Pharmaceuticals ICPT:US USD 55.29M 12.02M
Intrexon XON:US USD 11.51M 1.37M
IONIS PHARMACEUT IONS:US USD 47.95M 13.53M
Lexicon Pharmaceuticals LXRX:US USD 16.33M 3.75M
Ligand Pharmaceuticals LGND:US USD 31.13M 13.69M
Merk MRK:US USD 2.63B 134M
Omeros OMER:US USD 13.59M 1.39M
Regulus Therapeutics RGLS:US USD 4.44M 2.18M
Sangamo Biosciences SGMO:US USD 16.44M 205K
Spectrum Pharmaceuticals SPPI:US USD 8.26M 1.12M
Takeda 4502:JP JPY 262.3B 13.57B
Vital Therapies VTL:US USD 3.62M 43K
YTE INCY:US USD 272.82M 6.36M